Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib
about
RTEL1 tagging SNPs and haplotypes were associated with glioma developmentAssociation Study of a Functional Variant on ABCG2 Gene with Sunitinib-Induced Severe Adverse Drug ReactionRole of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients.Critical appraisal of sorafenib in the treatment of Chinese patients with renal cell carcinomaThe association of platelet count with clinicopathological significance and prognosis in renal cell carcinoma: a systematic review and meta-analysis.Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma.Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma.Prognostic Biomarkers for Response to Vascular Endothelial Growth Factor-Targeted Therapy for Renal Cell Carcinoma.Genetic variation in the GSTM3 promoter confer risk and prognosis of renal cell carcinoma by reducing gene expression.Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma.Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients.VEGF pathway polymorphisms as prognostic and pharmacogenetic factors in cancer: a 2013 update.Pharmacogenetics of the nuclear hormone receptors: the missing link between environment and drug effects?Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agents.Pharmacogenomic biomarkers for personalized cancer treatment.Clinical and molecular prognostic and predictive biomarkers in clear cell renal cell cancer.Predictive molecular biomarkers to guide clinical decision making in kidney cancer: current progress and future challenges.Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature.Tumour and patient factors in renal cell carcinoma-towards personalized therapy.Predictive biomarker candidates to delineate efficacy of antiangiogenic treatment in renal cell carcinoma.Potential protective role of Grainyhead-like genes in the development of clear cell renal cell carcinoma.A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review.Pregnane X receptor, constitutive androstane receptor and hepatocyte nuclear factors as emerging players in cancer precision medicine.Precision medicine from the renal cancer genome.Feasibility, efficacy and safety of tyrosine kinase inhibitor treatment in hemodialyzed patients with renal cell cancer: 10 years of experience.Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action.Sunitinib in kidney cancer: 10 years of experience and development.Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib-Treated Cancer.Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients.Effects of VEGF and VEGFR polymorphisms on the outcome of patients with metastatic renal cell carcinoma treated with sunitinib: a systematic review and meta-analysis.Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib.PAN-cancer analysis of S-phase enriched lncRNAs identifies oncogenic drivers and biomarkers.Tumour cell expression of interleukin 6 receptor α is associated with response rates in patients treated with sunitinib for metastatic clear cell renal cell carcinoma.Kidney cancer: Single nucleotide polymorphisms in mRCC-is their time up?Association analysis of SNPs present in plasma with adverse events and population pharmacokinetics in Chinese sunitinib treated patients with renal cell carcinoma.Hypothyroidism as a potential biomarker of efficacy of famitinib, a novel VEGFR-2 inhibitor in metastatic breast cancer.Cytochromes P450 1A2 and 3A4 Catalyze the Metabolic Activation of Sunitinib.Single nucleotide polymorphisms of the vascular endothelial growth factor receptor - a promising biomarker in metastatic renal cell carcinoma.Impact of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) single nucleotide polymorphisms on outcome in gastroenteropancreatic neuroendocrine neoplasms.
P2860
Q28383341-79AB6427-263A-47BC-A8B5-955F96E844F6Q28550377-8EA821DC-4BA2-44D7-BF04-ADB1C16C9F60Q33418378-D3406941-22EC-4A81-8D4B-23EB7F2C427EQ33754122-2BE853C1-CF2D-4C1F-B023-A7413FFFCD8BQ35625163-20297324-8FCE-4942-8D16-BF9BD8BF61D2Q35921573-B522DAB5-82EB-42DF-9903-54C280C94D04Q36275134-E654A367-5051-4725-9077-4F1954B25624Q36893510-350FC3E0-3798-4A8E-871C-401992623554Q37385267-B09D09E4-41DE-4337-84C4-AAA6B0C527BBQ37470058-458BAAF4-6443-48F1-A493-5A0B8FD35860Q37702070-62FBAE98-4B0E-48C4-BE78-666F68BB8BABQ38148602-2EEF0739-EA9A-49C4-AC4B-809BCAFBCA4BQ38166454-7A3599C7-F209-4A99-B53A-472379DADEE1Q38196855-1EC97D99-3D8B-46AF-8A36-C9F847932354Q38262008-522CEABC-0605-4A70-9938-AB251B1A5324Q38294622-412F3523-FD2B-461D-86C3-BCF3FCA26B40Q38402997-1C0CFA69-3B0C-4DA7-9150-42FF76079C99Q38414396-D6B8FD23-07F0-4F0A-A43B-4FD23A023BF1Q38418649-60973E56-54EB-4D1A-A24F-460871E122A6Q38546217-2533658B-9E76-4FF8-B710-9346020D59CBQ38702306-4720C613-44E3-4905-8DDD-7474230C7DE4Q38720430-6934D394-5321-426F-B046-628930FBA384Q38937177-4C47A150-B28F-41B2-B2A5-79050B90C73EQ38970282-B859BE60-C81C-4191-AA34-2092BDC158E5Q38975599-152A434D-3873-4A37-9219-41DE8C8E6998Q39008859-84D2E73C-B592-4F41-9110-F7E7A70651E3Q39038214-677B477A-1325-4F31-8C5B-4EF4E3EBCAA4Q40177329-E109BAD2-2E78-4D42-BED9-909BC5B35B3FQ40875500-56EE64BD-B3E1-4D83-BB4B-A0238783F0A3Q41921665-79E37B37-44F9-4B5C-B545-4DA23EFFDBAAQ46245352-56F88264-8FE9-40F9-848D-9358B1A9499EQ52371386-3A750AE5-DF27-48E2-8AE3-EB6D01E51A97Q52582783-E252FC06-FDEB-4B04-95B5-DA698B4DC929Q53448682-0FEC2A97-2717-4911-90E3-26394B3AA109Q54119194-516F4D9E-E047-4422-9DC1-06F5B4A47509Q54344097-03414757-5E16-4DD4-9D3C-8DF0CCA0499BQ54977664-A6F04284-9480-4E44-B418-2BBDD357109EQ55007866-5700D596-25F1-4EC6-A869-37AB86E858B0Q55536886-B647DA6A-0825-4514-8400-E6CBE7EF0D7A
P2860
Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Single-nucleotide polymorphism ...... rcinoma treated with sunitinib
@ast
Single-nucleotide polymorphism ...... rcinoma treated with sunitinib
@en
type
label
Single-nucleotide polymorphism ...... rcinoma treated with sunitinib
@ast
Single-nucleotide polymorphism ...... rcinoma treated with sunitinib
@en
prefLabel
Single-nucleotide polymorphism ...... rcinoma treated with sunitinib
@ast
Single-nucleotide polymorphism ...... rcinoma treated with sunitinib
@en
P2093
P2860
P356
P1476
Single-nucleotide polymorphism ...... rcinoma treated with sunitinib
@en
P2093
A Karadimou
A de la Taille
B Beuselinck
C Linassier
P2860
P2888
P304
P356
10.1038/BJC.2012.548
P407
P577
2013-03-01T00:00:00Z